<DOC>
	<DOCNO>NCT02922543</DOCNO>
	<brief_summary>To understand safety efficacy Revlimid® 5 mg Capsules ( hereinafter refer Revlimid ) patient `` relapsed refractory multiple myeloma '' ( hereinafter refer `` relapsed refractory MM '' ) receive long-term treatment actual condition use . 1 . Planned registration period This period start date initial marketing Revlimid end time plan number patient enrol , 300 , reach ( estimate approximately 1 year 3 moth ) . 2 . Planned surveillance period This period start date initial marketing Revlimid end 3 year last enrol patient begin receive Revlimid ( estimate approximately 4 year 3 month ) .</brief_summary>
	<brief_title>A Safety Efficacy Study Revlimid® 5 mg Capsules Patients With Relapsed Refractory Multiple Myeloma Who Have Received Long-term Treatment With Under Actual Condition Use</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Relapsed refractory MM patient special useresults surveillance ( allcase surveillance ) ( hereinafter refer allcase surveillance ) receive Revlimid treatment least 7 cycle institution cooperate perform allcase surveillance surveillance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Teratogenicity</keyword>
	<keyword>Thrombocytopenia haemorrhage</keyword>
	<keyword>Neutropenia infection</keyword>
	<keyword>Venous thromboembolism</keyword>
	<keyword>Allergic reaction</keyword>
	<keyword>Diarrhoea constipation</keyword>
	<keyword>Peripheral neuropathy</keyword>
	<keyword>Cardiac failure</keyword>
	<keyword>Arrhythmia</keyword>
	<keyword>Renal failure</keyword>
	<keyword>Myocardial infarction</keyword>
	<keyword>Interstitial lung disease</keyword>
	<keyword>Tumour lysis syndrome</keyword>
</DOC>